Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia
Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern
 Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.
 Due to inadequate gastric emptying, these patients often have symptoms of bloating, nausea
 and vomiting following ingestion of a meal. The goal of this study is to evaluate the effects
 of Itopride on gastric motor function and glycemia in patients with diabetes.
This is a mechanistic study evaluating in a cross-over design the effects of Itopride
 hydrochloride.

 The primary objective of this study is to evaluate the acute effects of itopride
 hydrochloride (200 mg three times daily) on gastric emptying of solid and liquid meal
 components in patients with type 1 and type 2 diabetes mellitus. Secondary objectives are to
 evaluate the effects of itopride hydrochloride on the glycaemic response to a meal,
 "meal-related" upper gastrointestinal symptoms and intragastric meal distribution.
Inclusion Criteria:

 -  Type-1 and Type-2 diabetic patients

 -  18 to 65 years old

 -  Glycated haemoglobin level (HbA1c) below 9%

 -  Body mass index (BMI) between 18 and 35 kg/m2

 Exclusion Criteria:

 -  Use of medications potentially influencing upper gastrointestinal motility or appetite
 within one week of the study (e.g. prokinetic drugs, macrolide antibiotics)

 -  Exposure to radiation for research purposes during the previous 12 months